Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01484145 · ClinicalTrials.gov registry record · Phase 2

Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

A Phase 2 study of Onychomycosis, sponsored by Nitric BioTherapeutics.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target
1
Study location

NCT01484145 is a Phase 2 study of Onychomycosis that has completed, run by Nitric BioTherapeutics. The registered enrollment target is 25 participants, below the 92-participant average among 11 other Onychomycosis trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01484145, a Phase 2 study of Onychomycosis, has completed, sponsored by Nitric BioTherapeutics.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine how much terbinafine is delivered to the nail bed after treatment with a number of modifications to a previously studied method for iontophoretic delivery of terbinafine gel. Iontophoretic delivery involves the use of a small electric charge to deliver drug across skin and nails.

Conditions Studied

Interventions

  • DRUG Terbinafine HCl

Study Locations (1)

Texas

  • Cetero Research - San Antonio

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2011-12
Est. Completion 2012-04
Phase Phase 2

Sponsor

Nitric BioTherapeutics

4 total trials

What the Registry Record Tells You About NCT01484145

The ClinicalTrials.gov registry entry for NCT01484145 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 11 other Onychomycosis trials with a reported enrollment target (73% lower). The listed sponsor is Nitric BioTherapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Onychomycosis appearing as the primary indexed condition, and to 1 intervention - of which Terbinafine HCl is the first listed.

NCT01484145 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01484145 about?

NCT01484145 is a clinical study titled "Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail". The purpose of this study is to determine how much terbinafine is delivered to the nail bed after treatment with a number of modifications to a previously studied method for iontophoretic delivery of terbinafine gel. Iontophoretic delivery involves the use of a small electric charge to deliver drug ...

What is the current status of trial NCT01484145?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-12. Estimated completion is 2012-04.

What conditions does trial NCT01484145 study?

This clinical trial studies the following conditions: Onychomycosis.

What interventions are being tested in trial NCT01484145?

The interventions under investigation include: Terbinafine HCl (DRUG).

Who is sponsoring clinical trial NCT01484145?

This trial is sponsored by Nitric BioTherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01484145 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Onychomycosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.